A phase I first-in-human clinical trial of ReS 39 in diabetes
Latest Information Update: 27 Jan 2021
At a glance
- Drugs ReS 39 (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions; First in man
- 27 Jan 2021 New trial record
- 21 Jan 2021 According to a reMYND media release, the company expects to initiate this trial during 2021.